Brommethylamin | 412270-64-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机溴化物
• 英文名称: Brommethylamin
• 英文别名: bromomethanamine
• CAS: 412270-64-5
• 化学式: CH₄BrN
• 分子量: 109.953
• InChiKey: QWVSXPISPLPZQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  3
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Brommethylamin 、 4-氯苯甲酰氯 以 二氯甲烷 、 水 为溶剂， 以96.5%的产率得到4-chloro-N-(bromomethyl)benzamide
  参考文献：
  名称：

  Lazabemide衍生物作为单胺氧化酶抑制剂的设计，合成和生物学评估

  摘要：

  在研究中，设计，合成和评估了一系列新的lazabemide衍生物作为单胺氧化酶（MAO-A或MAO-B）的抑制剂。这些化合物以拉沙贝米为先导化合物，并通过对烷基进行化合物的生物等排和修饰，对化学结构进行了修饰。通过对MAO的抑制活性来筛选两种抑制剂（对MAO-A的抑制和对MAO-B的抑制）。体外实验表明，化合物3a，3d和3f具有抑制MAO-A生物学活性的强度，而化合物3i和3m具有强度抑制MAO-B的生物学活性。从体外抑制活性实验的数据可以看出，化合物3d为IC 50  ＝ 3.12±0.05μmol/ mL的MAO-A，化合物3m为IC 50  ＝ 5.04±0.06μmol/ mL。通过检测血浆和脑组织中5-HT，NE，DA的含量以及MAO-A和MAO-B的活性，进行体内抑制活性实验以评估化合物3a，3d，3f，3i和3m的抑制活性。。体内抑制活性评估结果表明，化合物3a，3d，3f

  DOI：

  10.1016/j.bmc.2018.08.024
• 作为试剂：
  描述：

  2-噻吩甲酰肼 在 Brommethylamin 、 三甲胺 作用下， 生成 4-(3-cyanopropyl)-2-methoxy-N-(5- (thiophen-2-yl)-1,3,4-oxadiazol-2- yl)benzamide
  参考文献：
  名称：

  COMPOUNDS AND THEIR USES AS MIF INHIBITORS

  摘要：

  本发明提供了一种可以用作巨噬细胞迁移抑制因子（MIF）抑制剂的化合物I的公式；本发明化合物的制备方法；包括本发明化合物的药物组合物；以及通过给予本发明化合物来治疗由MIF介导的疾病的用途和方法。

  公开号：

  US20210403484A1

文献信息

• FLUORESCENTLY LABELED POLYSACCHARIDE, PREPARATION METHOD THEREFOR, AND USE THEREOF
  申请人：SUZHOU BAIYUAN GENT CO., LTD.

  公开号：US20210214559A1

  公开（公告）日：2021-07-15

  Disclosed is a fluorescently labeled polysaccharide. The fluorescently labeled polysaccharide is formed by covalently coupling a polysaccharide to a fluorescent dye having a structure as shown in Formula I. A stable covalent bond is form between the polysaccharide molecule and the fluorescent dye molecule. The fluorescently labeled polysaccharide has high stability in serum and other detection environments, has high biocompatibility, and is applicable to the detection of carbohydrate molecules inside and outside cells. Due to a large Stokes shift of the fluorescent dye molecule, the fluorescently labeled polysaccharide has advantages of high fluorescence stability, high fluorescence quantum yields, and achieves high signal-to-noise ratios in imaging results. Further disclosed is a method for preparing the fluorescently labeled polysaccharide. The method has mild reaction conditions and high reaction selectivity, is simple to execute, and can be used to prepare a fluorescently labeled polysaccharide in high yield.

  揭示了一种荧光标记的多糖。所述荧光标记的多糖是通过将多糖共价偶联到具有如公式I所示结构的荧光染料而形成的。多糖分子与荧光染料分子之间形成了稳定的共价键。荧光标记的多糖在血清和其他检测环境中具有高稳定性，具有高生物相容性，并适用于细胞内外碳水化合物分子的检测。由于荧光染料分子具有较大的Stokes位移，荧光标记的多糖具有高荧光稳定性、高荧光量子产率，并在成像结果中实现高信噪比的优势。进一步揭示了一种制备荧光标记的多糖的方法。该方法具有温和的反应条件和高反应选择性，操作简单，并可用于高产率制备荧光标记的多糖。
• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180086747A1

  公开（公告）日：2018-03-29

  The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein.

  本申请提供了化合物I或IA的化学式，或其药用可接受盐、异构体、互变异构体或其混合物，其中s、t、m、n、R1、R2、R3、R4、R5、R6和R7如本文所述。
• Latrunculin-Based Macrolides and Their Uses
  申请人：El Sayed Khalid

  公开号：US20110136880A1

  公开（公告）日：2011-06-09

  Latrunculin derivatives are disclosed, as are anti-invasive and cytotoxic uses for latrunculins and latrunculin derivatives, and semisyntheses of latrunculin derivatives. The latrunculins and latrunculin derivatives are useful, for example, in treating cancers.

  本文披露了Latrunculin衍生物，以及Latrunculins和Latrunculin衍生物的抗侵袭和细胞毒性用途，以及Latrunculin衍生物的半合成方法。例如，Latrunculins和Latrunculin衍生物在治疗癌症方面是有用的。
• Design, synthesis and biological activity of pyrazinamide derivatives for anti-<i>Mycobacterium tuberculosis</i>
  作者：Shiyang Zhou、Shanbin Yang、Gangliang Huang

  DOI：10.1080/14756366.2017.1367774

  日期：2017.1.1

  A total of 11 pyrazinamide derivatives were designed and synthesised using pyrazinamide as the lead compound, which was optimised by structural modification with alkyl chains, six-membered rings, and bioisosterism, respectively. The target compounds were synthesised using pyrazinecarboxylic acid as the starting material by acylation, amidation, and alkylation, respectively. Their structures were confirmed by H-1 NMR, C-13 NMR, HRESIMS, and elemental analysis, respectively. The bioactivities of derivatives were assayed using bacteriostatic experiment and minimum inhibitory concentration experiment. It was showed that the derivatives had good inhibitory effect on Mycobacterium tuberculosis. The biological activity of derivative 1f was the best among all compounds, its antibacterial activity was 99.6%, and the minimum inhibitory concentration was 8.0 mu g/mL.
• Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase
  作者：Shiyang Zhou、Guangying Chen、Gangliang Huang

  DOI：10.1016/j.bmc.2018.08.024

  日期：2018.9

  In the studied a series novel of lazabemide derivatives were designed, synthesized and evaluated as inhibitors of monoamine oxidase (MAO-A or MAO-B). These compounds used lazabemide as the lead compound, and the chemistry structures were modified by used the bioisostere and modification of compound with alkyl principle. The two types of inhibitors (inhibition of MAO-A and inhibition of MAO-B) were

  在研究中，设计，合成和评估了一系列新的lazabemide衍生物作为单胺氧化酶（MAO-A或MAO-B）的抑制剂。这些化合物以拉沙贝米为先导化合物，并通过对烷基进行化合物的生物等排和修饰，对化学结构进行了修饰。通过对MAO的抑制活性来筛选两种抑制剂（对MAO-A的抑制和对MAO-B的抑制）。体外实验表明，化合物3a，3d和3f具有抑制MAO-A生物学活性的强度，而化合物3i和3m具有强度抑制MAO-B的生物学活性。从体外抑制活性实验的数据可以看出，化合物3d为IC 50  ＝ 3.12±0.05μmol/ mL的MAO-A，化合物3m为IC 50  ＝ 5.04±0.06μmol/ mL。通过检测血浆和脑组织中5-HT，NE，DA的含量以及MAO-A和MAO-B的活性，进行体内抑制活性实验以评估化合物3a，3d，3f，3i和3m的抑制活性。。体内抑制活性评估结果表明，化合物3a，3d，3f